11 results
Venous Thromboembolism Treatment Algorithm
Branch points: 
Active bleeding?  Active malignancy? Provoked?

- Dr. Joseph Shatzel
@Clotmaster

#Management #VTE #DVT
Algorithm Branch ... points: Active bleeding ... #Management #VTE ... #DVT #Algorithm ... #Hematology #Anticoagulation
Treatment algorithm for VTE in Malignancy

(A) Suggested treatment algorithm for symptomatic and incidental DVT or PE
Treatment algorithm ... and incidental DVT ... without concomitant DVT ... #Cancer #Algorithm ... #Anticoagulation
Lower Extremity Venous Thrombosis - Management and Anatomy

Deep - Superficial - Active Bleeding

#LowerExtremity #Veins #Venous #Thrombosis
Superficial - Active Bleeding ... Superficial #Deep #VTE ... #DVT #Hematology ... Management #Anatomy #Anticoagulation ... #Algorithm
Bleeding risk calculators - HAS-BLED (atrial fibrillation) and IMPROVE (VTE prophylaxis for inpatients)
Important notes:
 • No
- HAS-BLED (atrial ... ) and IMPROVE (VTE ... validated for VTE ... treatment, only ... of withholding anticoagulation
Patient risk stratification algorithm for the treatment of cancer-associated thrombosis.

Currently, edoxaban and rivaroxaban are the only
stratification algorithm ... for the treatment ... DVT = deep vein ... #Cancer #Algorithm ... #Anticoagulation
►
Longterm Venous Thromboembolism Treatment Algorithm
Treat for 3 months and reassess
 • Isolated distal DVT (without cancer)
Thromboembolism Treatment ... Algorithm Treat ... Isolated distal DVT ... therapy - Second VTE ... #hematology #anticoagulation
Clotmaster Consensus 2019: Duration of Therapy for Venous Thromboembolic Disease
 • Superficial Venous Thrombosis
 • Upper
Upper Extremity DVT ... Thrombophilia • Cancer ... DeLoughery @Bloodman #VTE ... #anticoagulation ... hematology #length #treatment
Managing warfarin INR

Warfarin dosage must be individualized according to the patient's response to the drug, and
Over-anticoagulation ... lead to severe bleeding ... #management #algorithm ... #pharmacology #treatment ... #decisionaid #cardiology
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

https://www.nejm.org/doi/full/10.1056/NEJMoa1711948

Authors’ Conclusions: “Oral edoxaban was noninferior to subcutaneous dalteparin
Edoxaban for the Treatment ... of Cancer-Associated ... respect to recurrent VTE ... VenousThromboembolism #VTE ... VisualAbstract #DVT
Preoperative Risk Evaluation

Major Pre-Op Questions:
1. Does the patient have any modifiable risk factors that could be
event, follow ACC algorithm ... Anticoagulation ... - what is the bleeding ... one post op Cardiology ... • <3mo since VTE